Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives.
Cutaneous T-cell lymphomas
Mycosis fungoides
Sézary syndrome
immune-checkpoint-inhibitors
immunotherapy
nivolumab
pembrolizumab
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
06
2021
accepted:
30
07
2021
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
7
9
2021
Statut:
epublish
Résumé
Primary cutaneous T-cell lymphomas (PCTCL) are the most common types of cutaneous lymphomas, with Mycosis fungoides as the most frequent subtype. Besides early stages which usually have a good prognosis, advanced stages remain a great therapeutic challenge with low survival rates. To date, none of the currently available therapeutic options have significantly improved the outcomes of advanced cutaneous lymphomas. Recent studies have demonstrated that immune-checkpoint molecules, such as PD-1 and CTLA-4, play part in the proliferation pathways of neoplastic T-cells, as well as in other tumors. Hence, the potential role of immune-checkpoint-inhibitors in treating cutaneous lymphomas has been investigated in the last years. Herein, we outline the current knowledge regarding the role of immune-checkpoint molecules in PCTCL, their signaling pathways, microenvironment and therapeutic inhibition rationale. Moreover, we review the published data on immunotherapies in PCTCL and summarize the currently ongoing clinical trials in this field.
Identifiants
pubmed: 34485162
doi: 10.3389/fonc.2021.733770
pmc: PMC8415544
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
733770Informations de copyright
Copyright © 2021 Roccuzzo, Giordano, Fava, Pileri, Guglielmo, Tonella, Sanlorenzo, Ribero, Fierro and Quaglino.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Genet Genomic Med. 2015 Mar;3(2):130-6
pubmed: 25802883
Am J Hematol. 2011 Mar;86(3):325-7
pubmed: 21328438
J Invest Dermatol. 1995 Dec;105(6):855-6
pubmed: 7490483
Melanoma Res. 2020 Oct;30(5):515-518
pubmed: 32898391
Histopathology. 2015 Jan;66(2):173-81
pubmed: 24766213
Lancet Oncol. 2018 Sep;19(9):1192-1204
pubmed: 30100375
Cancer Immunol Immunother. 2018 Mar;67(3):423-434
pubmed: 29204699
J Cutan Med Surg. 2019 Sep/Oct;23(5):537-544
pubmed: 31353944
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Arch Dermatol. 2012 Dec;148(12):1379-85
pubmed: 23247480
Clin Cancer Res. 2012 Sep 15;18(18):5051-60
pubmed: 22850569
Blood Adv. 2019 Feb 26;3(4):519-530
pubmed: 30770361
Cell Rep. 2014 Jan 30;6(2):366-76
pubmed: 24412367
Prog Exp Tumor Res. 1970;13:1-27
pubmed: 4921480
Clin Cancer Res. 2015 Jan 15;21(2):274-85
pubmed: 25376389
Eur J Dermatol. 2014 Nov-Dec;24(6):670-5
pubmed: 25672788
PLoS One. 2017 Jun 8;12(6):e0179201
pubmed: 28594868
Int J Dermatol. 2010 Apr;49(4):390-5
pubmed: 20465692
J Invest Dermatol. 2017 Jan;137(1):257-260
pubmed: 27592800
Leuk Lymphoma. 2008 Jun;49(6):1190-201
pubmed: 18569641
Leuk Lymphoma. 2019 Aug;60(8):1899-1907
pubmed: 30638415
J Clin Oncol. 2016 Aug 10;34(23):2698-704
pubmed: 27269947
Br J Dermatol. 2014 Mar;170(3):720-4
pubmed: 24438061
J Am Acad Dermatol. 2010 Jun;62(6):995-1004
pubmed: 20466174
Int J Cancer. 2014 May 1;134(9):2136-45
pubmed: 24127318
Int J Cancer. 2007 Dec 15;121(12):2585-90
pubmed: 17721918
Eur J Cancer. 2017 May;77:57-74
pubmed: 28365528
Acta Derm Venereol. 2012 May;92(3):269-75
pubmed: 22678564
Leuk Lymphoma. 2018 Mar;59(3):562-577
pubmed: 29308723
Eur Rev Med Pharmacol Sci. 2014;18(4):553-8
pubmed: 24610622
Leuk Lymphoma. 2013 Apr;54(4):819-26
pubmed: 22946664
J Am Acad Dermatol. 1995 Mar;32(3):448-53
pubmed: 7868714
J Virol. 2006 Nov;80(22):11398-403
pubmed: 16956940
Oncoimmunology. 2020 Mar 18;9(1):1738797
pubmed: 32760603
Int Arch Allergy Immunol. 2020;181(10):733-745
pubmed: 32690848
J Cutan Pathol. 2010 May;37(5):535-41
pubmed: 19674197
Dermatol Clin. 1994 Apr;12(2):271-82
pubmed: 7913887
Nat Cell Biol. 2015 Feb;17(2):170-82
pubmed: 25580734
Curr Top Microbiol Immunol. 2011;350:17-37
pubmed: 21061197
JAAD Case Rep. 2015 Apr 11;1(2):99-100
pubmed: 27051697
Clin Lung Cancer. 2017 Sep;18(5):444-459.e1
pubmed: 28416123
Cancer. 2012 Dec 1;118(23):5830-9
pubmed: 22674564
Br J Dermatol. 2019 Mar;180(3):443-444
pubmed: 30821385
J Clin Oncol. 2015 Nov 10;33(32):3766-73
pubmed: 26438120
Arch Dermatol. 2004 Sep;140(9):1057-61
pubmed: 15381544
JAAD Case Rep. 2021 Jan 10;9:39-41
pubmed: 33644277
Clin Exp Metastasis. 2016 Oct;33(7):629-35
pubmed: 27380916
Leukemia. 2012 Mar;26(3):424-32
pubmed: 21904385
Eur J Dermatol. 2016 Dec 1;26(6):566-571
pubmed: 27545221
Postepy Dermatol Alergol. 2020 Oct;37(5):796-799
pubmed: 33240023
Nature. 2017 Dec 7;552(7683):121-125
pubmed: 29143824
Arch Dermatol. 2010 Dec;146(12):1382-8
pubmed: 20713771
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32114498
Leukemia. 2006 Oct;20(10):1759-66
pubmed: 16932349
Cancer Res. 2016 Nov 1;76(21):6241-6252
pubmed: 27634769
Eur Urol. 2018 Sep;74(3):309-321
pubmed: 29656851
JAMA Oncol. 2020 Mar 1;6(3):375-384
pubmed: 31876895
Eur J Haematol. 2003 Oct;71(4):250-6
pubmed: 12950233
J Am Acad Dermatol. 2005 Jan;52(1):32-9
pubmed: 15627078
Immunity. 2004 Aug;21(2):137-48
pubmed: 15308095
Nature. 2006 Sep 21;443(7109):350-4
pubmed: 16921384
Cancer Immunol Immunother. 2019 May;68(5):823-833
pubmed: 30302498
Blood. 2015 May 28;125(22):3393-400
pubmed: 25833961
J Clin Oncol. 2020 Jan 1;38(1):20-28
pubmed: 31532724
Am J Dermatopathol. 2012 Feb;34(1):126-8
pubmed: 22094231
Photodermatol Photoimmunol Photomed. 2015 Jul;31(4):184-94
pubmed: 25772268
J Clin Oncol. 2010 Nov 1;28(31):4730-9
pubmed: 20855822
Nat Med. 2006 Oct;12(10):1198-202
pubmed: 16917489
Ann Oncol. 2017 Oct 1;28(10):2517-2525
pubmed: 28961843
Chin Clin Oncol. 2019 Feb;8(1):11
pubmed: 30691274
Blood Adv. 2020 Jun 9;4(11):2489-2500
pubmed: 32502269
Cancer Immunol Res. 2018 Aug;6(8):900-909
pubmed: 29895574
Lancet. 2017 Aug 5;390(10094):555-566
pubmed: 28600132
JAMA Dermatol. 2013 Nov;149(11):1295-9
pubmed: 24005876
Blood. 2007 Jan 1;109(1):31-9
pubmed: 16960145
Blood. 2005 May 15;105(10):3768-85
pubmed: 15692063
J Clin Oncol. 2010 Oct 10;28(29):4485-91
pubmed: 20697094
Blood. 2007 Sep 15;110(6):1713-22
pubmed: 17540844
Leukemia. 2006 Jun;20(6):1123-9
pubmed: 16557241
Blood. 2014 Feb 20;123(8):1159-66
pubmed: 24335103
Br J Dermatol. 2019 Aug;181(2):350-357
pubmed: 30267549
Science. 2014 Nov 21;346(6212):945-9
pubmed: 25414302
Nat Rev Immunol. 2009 Oct;9(10):679-91
pubmed: 19763149
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
J Invest Dermatol. 2021 Mar;141(3):484-495
pubmed: 33162051
J Cutan Pathol. 2008 Nov;35(11):1032-9
pubmed: 18681861
Arch Dermatol. 2003 Jul;139(7):857-66
pubmed: 12873880
J Immunol. 2010 May 1;184(9):5232-41
pubmed: 20357262
Leukemia. 2007 Dec;21(12):2512-8
pubmed: 17713545
Trends Immunol. 2014 Feb;35(2):51-60
pubmed: 24210163
J Natl Compr Canc Netw. 2020 May;18(5):522-536
pubmed: 32380458
Br J Dermatol. 2015 Jul;173(1):93-105
pubmed: 25864856
Exp Dermatol. 2016 Feb;25(2):107-12
pubmed: 26441016
Asian Pac J Cancer Prev. 2015;16(13):5359-64
pubmed: 26225678
Blood Adv. 2021 Feb 9;5(3):771-774
pubmed: 33560388
Blood Adv. 2020 Oct 27;4(20):5203-5214
pubmed: 33095875
Sci Immunol. 2018 Nov 23;3(29):
pubmed: 30470696
Blood. 2010 Aug 5;116(5):767-71
pubmed: 20484084
Clin Transl Oncol. 2020 Jul;22(7):1059-1066
pubmed: 31696413
Br J Dermatol. 2014 Jun;170(6):1226-36
pubmed: 24641480
Front Immunol. 2020 Nov 23;11:561234
pubmed: 33329522
Nat Genet. 2015 Sep;47(9):1056-60
pubmed: 26258847
Br J Dermatol. 2002 Dec;147(6):1171-9
pubmed: 12452867
J Allergy Clin Immunol. 2009 May;123(5):1142-9, 1149.e1-5
pubmed: 19275959
Dermatol Clin. 1994 Apr;12(2):255-70
pubmed: 8045037
J Invest Dermatol. 2006 Oct;126(10):2217-23
pubmed: 16741512
Leuk Lymphoma. 2011 Mar;52(3):491-501
pubmed: 20846094
J Invest Dermatol. 1994 Nov;103(5):669-73
pubmed: 7963654
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Br J Dermatol. 2014 Sep;171(3):499-504
pubmed: 24601935
Eur J Cancer. 1997 Sep;33(10):1685-92
pubmed: 9389934
Clin Cancer Res. 2008 Feb 1;14(3):646-53
pubmed: 18245523
Curr Opin Oncol. 2016 Jan;28(1):88-96
pubmed: 26632770
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv30-iv40
pubmed: 29878045